The Role of GLP-1 Receptor Agonists in the Management of Polycystic Ovary Syndrome: A Narrative Review
DOI:
https://doi.org/10.12775/QS.2026.67.74171Keywords
Polycystic ovary syndrome, GLP-1 RAs, liraglutide, insulin resistance, semaglutide, obesity, infertilityAbstract
Background: Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Insulin resistance and obesity are frequent components of this syndrome and further worsen the associated hormonal disturbances and infertility.
Aim: The aim of this narrative review is to explore the potential role of GLP-1 receptor agonists (GLP-1 RAs) in the management of women with PCOS, with particular focus on their effects on blood glucose fluctuations and excess body weight, both of which are important targets in PCOS treatment.
Methods: The literature search was conducted using the PubMed database in order to find articles reporting on the mechanism of action of GLP-1 RAs, the results of their use in PCOS treatment, and their adverse effects. The authors included articles published between 2020 and 2026.
Results: GLP-1 RAs exhibit pleiotropic metabolic effects, including the regulation of insulin and glucagon secretion, protective effects on pancreatic beta-cells, and modulation of appetite and energy intake. These mechanisms may contribute to the beneficial clinical outcomes observed in women with PCOS. Current clinical studies and meta-analyses have demonstrated the positive effects of GLP-1 RAs on anthropometric parameters, glucose metabolism, and selected reproductive and hormonal functions, particularly when used in combination with metformin. Adverse effects associated with these agents are mainly gastrointestinal and generally diminish over the course of treatment.
Conclusions: GLP-1 RAs appear to represent a promising therapeutic approach for women with PCOS. However, further studies are required to evaluate the long-term effects of their use in this patient population.
References
1. Siddiqui S, Mateen S, Ahmad R, Moin S. A brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS). J Assist Reprod Genet. 2022 Nov;39(11):2439-73. https://doi.org/10.1007/s10815-022-02625-7
2. Celik O, Yazici D, Ciudin A et al. GLP-1 Receptor Analogs: Evidence Linking to Effect on Metabolic and Reproductive Functions in Patients with PCOS and Obesity. Obes Facts. 2026;19(1):93-108. https://doi.org/10.1159/000547055
3. Joshi A. PCOS stratification for precision diagnostics and treatment. Front Cell Dev Biol. 2024 Feb 8;12:1358755. https://doi.org/10.3389/fcell.2024.1358755
4. Purwar A, Nagpure S. Insulin Resistance in Polycystic Ovarian Syndrome. Cureus. 2022 Oct 16;14(10):e30351. https://doi.org/10.7759/cureus.30351
5. Houston EJ, Templeman NM. Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS. J Endocrinol. 2025 Mar 12;265(2):e240269. https://doi.org/10.1530/joe-24-0269
6. Armanini D, Boscaro M, Bordin L, Sabbadin C. Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism. Int J Mol Sci. 2022 Apr 8;23(8):4110. https://doi.org/10.3390/ijms23084110
7. Harada M. Pathophysiology of polycystic ovary syndrome revisited: Current understanding and perspectives regarding future research. Reprod Med Biol. 2022 Oct 8;21(1):e12487. https://doi.org/10.1002/rmb2.12487
8. Sanchez-Garrido MA, Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab. 2020 May;35:100937. https://doi.org/10.1016/j.molmet.2020.01.001
9. Xu Y, Qiao J. Association of Insulin Resistance and Elevated Androgen Levels with Polycystic Ovarian Syndrome (PCOS): A Review of Literature. J Healthc Eng. 2022 Mar 21;2022:9240569. https://doi.org/10.1155/2022/9240569
10. Di Lorenzo M, Cacciapuoti N, Lonardo MS et al. Pathophysiology and Nutritional Approaches in Polycystic Ovary Syndrome (PCOS): A Comprehensive Review. Curr Nutr Rep. 2023 Sep;12(3):527-544. https://doi.org/10.1007/s13668-023-00479-8
11. Bednarz K, Kowalczyk K, Cwynar M et al. The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome. Int J Mol Sci. 2022 Apr 14;23(8):4334. https://doi.org/10.3390/ijms23084334
12. Ni M, Lei H, Ye T, Wang Y. Adipose-androgen crosstalk in polycystic ovary syndrome: mechanisms and therapeutic implications. Front Endocrinol (Lausanne). 2025 Dec 16;16:1731179. https://doi.org/10.3389/fendo.2025.1731179
13. Ee C, Pirotta S, Mousa A et al. Providing lifestyle advice to women with PCOS: an overview of practical issues affecting success. BMC Endocr Disord. 2021 Nov 23;21(1):234. https://doi.org/10.1186/s12902-021-00890-8
14. Zhao H, Zhang J, Cheng X et al. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. J Ovarian Res. 2023 Jan 11;16(1):9. https://doi.org/10.1186/s13048-022-01091-0
15. Nabrdalik K, Skonieczna-Żydecka K, Irlik K et al. Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials. Front Endocrinol (Lausanne). 2022 Sep 14;13:975912. https://doi.org/10.3389/fendo.2022.975912
16. Telagarapu VML, Nallamothu PD, Telagarapu VN et al. Revisiting Metformin in the Management of Polycystic Ovary Syndrome (PCOS). Cureus. 2025 Jul 18;17(7):e88216. https://doi.org/10.7759/cureus.88216
17. Rashid R, Mir SA, Kareem O et al. Polycystic ovarian syndrome-current pharmacotherapy and clinical implications. Taiwan J Obstet Gynecol. 2022 Jan;61(1):40-50. https://doi.org/10.1016/j.tjog.2021.11.009
18. Papaetis GS, Kyriacou A. GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: Current research and future horizons. Adv Clin Exp Med. 2022 Nov;31(11):1265-1274. https://doi.org/10.17219/acem/151695
19. Cena H, Chiovato L, Nappi RE. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. J Clin Endocrinol Metab. 2020 Aug 1;105(8):e2695–709. https://doi.org/10.1210/clinem/dgaa285
20. Abdalla MA, Deshmukh H, Atkin S, Sathyapalan T. The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence. Ther Adv Endocrinol Metab. 2021 Jan 27;12:2042018821989238. https://doi.org/10.1177/2042018821989238
21. Latif W, Lambrinos KJ, Patel P, Rodriguez R. Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs). 2024 Feb 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.
22. Szczesnowicz A, Szeliga A, Niwczyk O et al. Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies. J Clin Med. 2023 Sep 12;12(18):5915. https://doi.org/10.3390/jcm12185915
23. Frangie Machado M, Shunk T, Hansen G et al. Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review. Cureus. 2024 Aug 12;16(8):e66691. https://doi.org/10.7759/cureus.66691
24. Zhao X, Wang M, Wen Z et al. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front Endocrinol (Lausanne). 2021 Aug 23;12:721135. https://doi.org/10.3389/fendo.2021.721135
25. Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024 Jul 24;15:1431292. https://doi.org/10.3389/fendo.2024.1431292
26. Ard J, Fitch A, Fruh S, Herman L. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. Adv Ther. 2021 Jun;38(6):2821-2839. doi: 10.1007/s12325-021-01710-0. Epub 2021 May 11. https://doi.org/10.1007/s12325-021-01710-0
27. Moiz A, Filion KB, Tsoukas MA et al. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. Am J Med. 2025 Jun;138(6):934-940. https://doi.org/10.1016/j.amjmed.2025.01.021
28. Dong Y, Carty J, Goldstein N et al. Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo. Mol Metab. 2021 Dec;54:101352. https://doi.org/10.1016/j.molmet.2021.101352
29. Salvador J. GLP-1-based medications: mechanisms involved in obesity treatment. Med Clin (Barc). 2025;165(1):107035. https://doi.org/10.1016/j.medcle.2025.107035
30. Doval-Caballero JLE, Ferreira-Hermosillo A, Eugenio-Ponce GD et al. Potential role of glucagon like peptide 1 in taste receptors. Front Endocrinol (Lausanne). 2026 Jan 23;16:1683419. https://doi.org/10.3389/fendo.2025.1683419
31. Jalleh RJ, Plummer MP, Marathe CS et al. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. J Clin Endocrinol Metab. 2024 Dec 18;110(1):1-15. https://doi.org/10.1210/clinem/dgae719
32. Jalleh RJ, Marathe CS, Rayner CK et al. Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility. Endocrinology. 2024 Nov 26;166(1):bqae155. https://doi.org/10.1210/endocr/bqae155
33. Wang JY, Wang QW, Yang XY et al. GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach. Front Endocrinol (Lausanne). 2023 Feb 1;14:1085799. https://doi.org/10.3389/fendo.2023.1085799
34. van Zuylen ML, Siegelaar SE, Plummer MP et al. Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration. Br J Anaesth. 2024 Apr;132(4):644-648. https://doi.org/10.1016/j.bja.2024.01.001
35. Gofron KK, Wasilewski A, Małgorzewicz S. Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review. Nutrients. 2025 Apr 9;17(8):1303. https://doi.org/10.3390/nu17081303
36. Voros C, Chatzinikolaou F, Papapanagiotou I et al. A Systematic Review on GLP-1 Receptor Agonists in Reproductive Health: Integrating IVF Data, Ovarian Physiology and Molecular Mechanisms. Int J Mol Sci. 2026 Jan 12;27(2):759. https://doi.org/10.3390/ijms27020759
37. Bader S, Bhatti R, Mussa B, Abusanana S. A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS. Womens Health (Lond). 2024 Jan-Dec;20:17455057241234530. https://doi.org/10.1177/17455057241234530
38. Elkind-Hirsch KE, Chappell N, Shaler D et al. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertil Steril. 2022 Aug;118(2):371-381. https://doi.org/10.1016/j.fertnstert.2022.04.027
39. Carmina E, Longo RA. Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs. J Clin Med. 2023 Sep 12;12(18):5921. https://doi.org/10.3390/jcm12185921
40. Lin S, Deng Y, Huang J et al. Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials. Sci Rep. 2025 May 13;15(1):16512. https://doi.org/10.1038/s41598-025-99622-4
41. Chen H, Lei X, Yang Z et al. Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial. Reprod Biol Endocrinol. 2025 Jul 26;23(1):108. https://doi.org/10.1186/s12958-025-01447-3
42. Zhou L, Qu H, Yang L, Shou L. Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review. BMC Endocr Disord. 2023 Nov 8;23(1):245. https://doi.org/10.1186/s12902-023-01500-5
43. Thomsen RW, Mailhac A, Løhde JB, Pottegård A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):66-88. https://doi.org/10.1111/dom.16364
44. Liu L, Chen J, Wang L et al. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne). 2022 Dec 7;13:1043789. https://doi.org/10.3389/fendo.2022.1043789
45. Andreasen CR, Andersen A, Knop FK, Vilsbøll T. How glucagon-like peptide 1 receptor agonists work. Endocr Connect. 2021 Jul 17;10(7):R200-R212. https://doi.org/10.1530/EC-21-0130
46. Gill L, Mackey S. Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists. J Womens Health (Larchmt). 2021 Jul;30(7):1016-1027. https://doi.org/10.1089/jwh.2020.8683
47. He L, Wang J, Ping F et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2022 May 1;182(5):513-519. https://doi.org/10.1001/jamainternmed.2022.0338
48. Trujillo J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. J Clin Pharm Ther. 2020 Sep;45 Suppl 1(Suppl 1):43-60. https://doi.org/10.1111/jcpt.13225
49. Ibsen CK, Brostrøm Kousgaard M, Olsen S, Christiansen AL, Sandholdt CT, Rørth R, Overbeck G. Patients' experiences with GLP1-RAs - a systematic review. Scand J Prim Health Care. 2025 Jun;43(2):370-379. https://doi.org/10.1080/02813432.2025.2477141
50. Kourtidou C, Tziomalos K. Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome. Biomedicines. 2023 Feb 8;11(2):496. https://doi.org/10.3390/biomedicines11020496
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Angelika Juszczyk, Sylwia Pietrajtis, Bartłomiej Sałapski, Dominika Brożyna, Mateusz Kubicki, Damian Grębosz, Jakub Piec, Wiktoria Komornik, Michał Łebek, Krzysztof Lis
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 27
Number of citations: 0
